<DOC>
	<DOCNO>NCT02490176</DOCNO>
	<brief_summary>Glucagon-like peptide-1 ( GLP-1 ) incretin hormone regulate plasma glucose , GLP-1 analogues recently introduce treatment acute myocardial infarction . The investigator plan evaluate effect liraglutide haemodynamic parameter patient heart failure .</brief_summary>
	<brief_title>Effects Glucagon Like Peptide-1 Haemodynamic Parameters</brief_title>
	<detailed_description>Heart failure ( HF ) major cause morbidity mortality world wide . Glucagon-like peptide-1 ( GLP-1 ) incretin hormone regulate plasma glucose , direct effect cardiovascular system . In previous study , GLP-1 analogue liraglutide could improve leave ventricular function patient non-ST-segment elevation myocardial infarction . However , effect GLP-1 HF patient remain unclear . Pulse indicator continuous cardiac output ( PiCCO ) technology combination transpulmonary thermodilution pulse contour analysis , measure hemodynamic variable ( leave ventricular ejection fraction , volume , mass ) fast feasible way . Therefore , aim study evaluate effect liraglutide hemodynamic variable HF patient use PiCCO system .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients HF eligible study . Diagnosis HF base impaired ejection fraction ( &lt; 50 % ) . Patients also exclude follow reason : unconscious presentation ; valvular heart disease , cardiogenic shock , hypoglycaemia , diabetic ketoacidosis ; renal insufficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>